Denosumab: anti-RANKL antibody (Q28236159)

Current osteoporosis reports

Europe PubMed Central

title

Denosumab: anti-RANKL antibody (English)

0 references

1 reference

Paul D Miller

1

0 references

language of work or name

English

0 references

publication date

March 2009

0 references

published in

1 reference

Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling.

volume

7

0 references

issue

1

0 references

page(s)

18-22

0 references

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007/S11914-009-0004-5

Remodeling and skeletal fragility

21 January 2018

1 reference

12 December 2020

Osteoclast differentiation and activation

1 reference

12 December 2020

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial

1 reference

12 December 2020

Mechanisms of disease: is osteoporosis the obesity of bone?

1 reference

12 December 2020

PTH differentially regulates expression of RANKL and OPG.

1 reference

12 December 2020

Does early PTH treatment compromise bone strength? The balance between remodeling, porosity, bone mineral, and bone size

1 reference

12 December 2020

The effects of antifracture therapies on the components of bone strength: assessment of fracture risk today and in the future

1 reference

12 December 2020

Model structure and control of bone remodeling: a theoretical study.

1 reference

12 December 2020

Bone and fat connection in aging bone

1 reference

12 December 2020

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

1 reference

12 December 2020

Osteocytes: a proposed multifunctional bone cell.

1 reference

12 December 2020

Effects of human parathyroid hormone (1-34), LY333334, on bone mass, remodeling, and mechanical properties of cortical bone during the first remodeling cycle in rabbits

1 reference

12 December 2020

Osteocytes, mechanosensing and Wnt signaling

1 reference

12 December 2020

Wnt signaling: a win for bone

1 reference

12 December 2020

Denosumab in postmenopausal women with low bone mineral density

1 reference

12 December 2020

Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment

1 reference

12 December 2020

Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD

1 reference

12 December 2020

Bone's mechanostat: A 2003 update

1 reference

12 December 2020